Kringle Pharma Income Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	342.21	72	80	69	391	289
Revenue Growth	372.42%	-10.00%	15.94%	-82.35%	35.29%	-38.12%
Cost of Revenue	70.39	-	-	-	88	71
Gross Profit	271.82	72	80	69	303	218
Selling, General & Admin	1,077	300	254	242	196	178
Research & Development	-	681	643	716	533	398
Operating Expenses	1,077	981	897	958	729	576
Operating Income	-804.88	-909	-817	-889	-426	-358
Currency Exchange Gain (Loss)	1.91	-	-	-	21	-1
Other Non Operating Income (Expenses)	-3.83	-6	62	36	75	59
Pretax Income	-806.68	-915	-755	-853	-330	-300
Income Tax Expense	1.77	1	1	1	1	1
Net Income	-808.44	-916	-756	-854	-331	-301
Net Income to Common	-808.44	-916	-756	-854	-331	-301
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	7	7	6	5	5	4
Shares Outstanding (Diluted)	7	7	6	5	5	4
Shares Change	7.53%	6.92%	18.72%	11.00%	16.91%	7422.44%
EPS (Basic)	-110.24	-133.88	-118.14	-158.44	-68.16	-72.47
EPS (Diluted)	-110.24	-133.88	-118.14	-158.44	-68.16	-72.47
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Gross Margin	79.43%	100.00%	100.00%	100.00%	77.49%	75.43%
Operating Margin	-235.20%	-1262.50%	-1021.25%	-1288.41%	-108.95%	-123.88%
Profit Margin	-236.24%	-1272.22%	-945.00%	-1237.68%	-84.66%	-104.15%
EBIT	-804.88	-909	-817	-889	-426	-358
EBIT Margin	-235.20%	-	-	-	-108.95%	-123.88%